Entities

Carlton Weatherby serves as Chief Strategy and Growth Officer at Inspire Medical Systems.

Matt Osberg serves as Chief Financial Officer at Inspire Medical Systems.

Tim Herbert serves as Founder, Chairman, President and Chief Executive Officer at Inspire Medical Systems.

Inspire Medical Systems is a medical technology company developing implantable upper-airway neurostimulation for obstructive sleep apnea. Founded in 2007 as a Medtronic spinout and listed on the New York Stock Exchange as INSP since 2018, Inspire synchronizes stimulation of the hypoglossal nerve with breathing to help keep the airway open during sleep. Its neuroscience and deep technology work combines implantable electronics, nerve stimulation, physiological sensing and clinical device development. Inspire therapy is used in selected patients who cannot benefit from or tolerate positive airway pressure treatment; eligibility depends on clinical assessment and the applicable device labeling. The company's platform includes Inspire therapy and the SleepSync patient-management ecosystem. Founder Tim Herbert serves as Chairman, President and CEO; the current public leadership directory includes CFO Matt Osberg, Chief Strategy and Growth Officer Carlton Weatherby and Chief Operations and Innovation Officer Jason Kelly. Osberg's CFO appointment took effect February 17, 2026. Inspire also makes strategic investments in sleep-care technology: it invested $10 million in EnsoData in 2022, provided seed financing to Ognomy, and participated in EnsoData's 2025 Series B. Its implantable therapy and its investments in AI sleep diagnostics are distinct activities.

Tokyo-based drug discovery startup founded in June 2024 as a spinout from Asahi Kasei, developing cancer vaccines and immunotherapies using Sonanos hyaluronic-acid nanogel drug delivery. Its platform carries cancer antigens to lymph nodes and targets cDC1 dendritic cells to stimulate tumor-specific T-cell responses. It is advancing nonclinical vaccine development for difficult-to-treat solid tumors and collaborates with academic and pharmaceutical partners on shared neoantigens and cancer immunology. Its programs aim to treat tumors and prevent recurrence; clinical efficacy is not yet established.

Sendai-based venture capital firm wholly owned by Tohoku University, established in February 2015 to commercialize university research and build technology companies. It invests mainly at seed and early stages in deep-tech and life-sciences startups using research from Tohoku University and other national universities in the surrounding region. Its focus includes semiconductor devices, materials, drug discovery, space, green transformation and food technology. Its investment professionals help assemble management teams, match companies with executives and entrepreneurs in residence, and support industrial partnerships and global expansion. Its third fund began operating in June 2026.

President of Tohoku University Venture Partners since February 2026. Joined THVP in September 2025 after 34 years at Sumitomo Mitsui Banking Corporation and six years as president of SMBC Human Career, working on corporate banking, private advisory, human resources and executive recruitment.

Neurotechnology medical-device company founded in July 2023, with operations in the United States and Japan, developing a middleware platform that integrates symptom-specific hardware and software for brain-machine interfaces. Its first focus is restoring swallowing function in people with dysphagia, including after stroke. It is developing the implantable Swallow Autopilot device and a thin-film, multi-point electrode device for continuous swallowing assessment. Its research includes neural decoding and implantable neuromodulation with university partners. Both devices remain under development and have not received medical-device approval or clearance. Its Japanese operation is Ruten Japan G.K.

Shaheen Hamdy co-founded Phagenesis and is its chief scientific officer. A University of Manchester professor of neurogastroenterology, his research studies neuroplasticity and recovery of swallowing control after brain injury.

Ceara Chambers: Executive Assistant, Questa Capital.

Sara Tate: Executive Assistant, Questa Capital.

Julia Iglesias: Associate, Questa Capital.

Michael Davis: Associate, Questa Capital.

Jonathan Li: Associate, Questa Capital.

Chandler Lally: Vice President, Questa Capital.

Eric Thakor: Vice President, Questa Capital.

Evans Grenier: Vice President, Questa Capital.

Steph Scott: Vice President, Questa Capital.

Joe Huang: Chief Financial Officer, Questa Capital.

Justin Kirkpatrick: Partner, Questa Capital.

Shawn Conway: Managing Partner and COO, Questa Capital.

Bradley Sloan: Managing Partner, Questa Capital.

Questa Capital is a venture growth equity firm investing in expansion-stage healthcare services, healthcare technology and medical device companies. Its portfolio connects AI and neuroscience with clinical care through investments including EnsoData's AI sleep diagnostics, Eko's AI-enabled cardiac assessment, Cortica's neurocognitive care for children with autism, and Bicycle Health's virtual treatment for opioid use disorder. The firm supports companies entering commercial growth and combines concentrated equity investments with operational advice. Its public team includes Founder and Managing Partner Ryan Drant, Managing Partners Bradley Sloan and Shawn Conway, Partners Justin Kirkpatrick and Brian Butler, CFO Joe Huang, four Vice Presidents, three Associates and two Executive Assistants. Conway is also COO. Questa disclosed $199 million in commitments for Fund I, $348 million for Fund II and $397 million for Fund III. It reports approximately $1 billion under management across its platform. Questa led EnsoData's $20 million Series B announced June 25, 2025.

Brian Butler: Director, EnsoData.

John Rondoni: Director, EnsoData.

Fred Robertson: Director, EnsoData.

Angela Becker-Bradley: Human Resources Manager, EnsoData.

Rachel Boer: Senior Marketing Director, EnsoData.

Cameron Brackett: Vice President of Engineering, EnsoData.

Kelsey Buehl: Vice President of Customer Success, EnsoData.

Sigrid Schoepel: Vice President of Quality and Regulatory, EnsoData.

Yoav Nygate: Vice President of Artificial Intelligence, EnsoData.

Joe Austin: Senior Vice President of Global Business Development, EnsoData.

Fred Turkington: Senior Vice President of Product Management, EnsoData.

Bobby Cockrill: Chief Commercial Officer, EnsoData.

Matt Dobereiner: Chief Financial Officer, EnsoData.

Nathaniel Watson: Chief Medical Officer, EnsoData.

Brock Hensen: Chief Operating Officer, EnsoData.

Nick Glattard: Co-Founder and Chief Technology Officer, EnsoData.

Sam Rusk: Co-Founder and Chief AI Officer, EnsoData.

Chris Fernandez: Co-Founder, Executive Chairman and Chief Research Officer, EnsoData.

Justin Mortara: CEO, President and Director, EnsoData.

Clinical-stage neuroscience pharmaceutical company, formerly Sapient Therapeutics, developing prescription cannabinoid medicines for epilepsy and other neurological and psychiatric disorders. Its formulation technology turns synthetic cannabidiol into water-soluble preparations and solid oral doses for adult and pediatric patients. Its published pipeline includes focal epilepsy and schizophrenia programs. Avata operates across the UK, US and Australia and licenses its programs to Oceanus Bio for development in Japan and other Asian markets excluding China and India. Its UK holding company was incorporated in April 2022; the Avata rebrand was announced in May 2024.

Tokyo-based pharmaceutical company founded in May 2024 that licenses medicines from US and European biotech companies and develops them for Japan and Asia. It combines clinical development, regulatory work and commercialization to address the absence of overseas treatments in these markets. Its neuroscience work includes an oral cannabidiol drug program for epilepsy through a June 2025 co-development and exclusive regional licensing agreement with Avata Biosciences.

Linda Olson: Office Manager, Clarevia Ventures.

Becky Hoerman: Controller, Clarevia Ventures.

Shelly Lanning: Venture Partner, Clarevia Ventures.

Cheryl R. Blanchard: Executive in Residence, Clarevia Ventures.

Jenni Le: Principal, Clarevia Ventures.

Margaret Kaczor Andrew: Venture Partner, Clarevia Ventures.

Joe Amaral: Chief Medical and Scientific Officer, Clarevia Ventures.

John Neis: Partner, Clarevia Ventures.

David Arnstein: Partner and CFO, Clarevia Ventures.

Paul Weiss: Partner, Clarevia Ventures.

Scott Button: Partner, Clarevia Ventures.

Clarevia Ventures is a Midwest healthcare venture capital firm formerly known as Venture Investors Health Fund. It announced the rebrand on May 6, 2026 and invests in early-stage medical devices, diagnostics, digital health and pharmaceutical innovations, including university research spinouts. Its AI, deep technology and neuroscience portfolio includes EarliPoint Health's eye-tracking autism assessment, EnsoData's AI sleep testing, Neurovance's neuropsychiatric therapeutics and HistoSonics' ultrasound-based tissue treatment. Its public team directory lists Managing Partner Jim Adox, Partners Scott Button, Paul Weiss, David Arnstein and John Neis, Chief Medical and Scientific Officer Joe Amaral, Principal Jenni Le, Venture Partners Margaret Kaczor Andrew and Shelly Lanning, Executive in Residence Cheryl R. Blanchard, Controller Becky Hoerman and Office Manager Linda Olson. Arnstein is also CFO. The firm closed Venture Investors Health Fund 6 at $75 million in October 2019 and its seventh fund at $80 million in September 2025. It co-led EarliTec's $21.5 million Series B in April 2024. Its current materials report $350 million under management; this represents firm assets across vehicles.

Jim Adox: Director, EarliPoint Health.

Maria Kousi: Director, EarliPoint Health.

Jim Grien: Director, EarliPoint Health.

Mike Vassar: Director of Sales, EarliPoint Health.

Robin Sifre: Director of R&D, EarliPoint Health.

Ella Swanson-Hysell: Director of Product Management and Innovation, EarliPoint Health.

Ryan Bormann: Director of Operations and Quality, EarliPoint Health.

Christopher MacAloon: Executive Vice President of Operations, EarliPoint Health.

Pete Polgar: Vice President of Marketing, EarliPoint Health.

Leota Pearson: Chief Financial Officer, EarliPoint Health.

Cheryl Tierney: Chief Medical Officer, EarliPoint Health.

Ami Klin: Scientific Founder and Chief Clinical Officer, EarliPoint Health.

Warren Jones: Scientific Founder, EarliPoint Health.

EarliPoint Health is the current brand of EarliTec Diagnostics, a medical device company using eye tracking and software analysis to help clinicians assess autism and associated developmental differences. Its technology originated in research at Children's Healthcare of Atlanta, Emory University and Yale University; the company describes its underlying platform as multimodal AI. EarliPoint Assessment measures visual engagement while a child watches videos. FDA clearance K253442, issued March 5, 2026, covers use as an aid to qualified clinicians assessing children aged 16 through 95 months who are at risk of autism. It is a prescription clinician tool. EarliTec announced its EarliPoint Health rebrand in October 2025. President and CEO Jamie Pagliaro began the role August 1, 2025; scientific founders include Warren Jones and Chief Clinical Officer Ami Klin. The company announced a $19.5 million Series A in February 2022 and a $21.5 million Series B in April 2024. An April 2026 SEC filing reports $3.5 million of debt sold in an ongoing $7 million offering.

Jamie Pagliaro: President, CEO and Director, EarliPoint Health.

Diagnostics branch of APRINOIA Therapeutics developing tools for early detection and differentiation of neurodegenerative diseases. It develops the APN-1607 (florzolotau) tau PET imaging tracer and works on blood tests, brain-focused PET systems and AI image interpretation. It aims to combine these technologies in a brain-health management platform for disease staging, monitoring and personalized care. Its published pipeline lists the tracer in Phase III development for Alzheimer’s disease in China; its June 2025 release describes ongoing regulatory review in Taiwan.

Neuroscience biotechnology company founded in 2015 that develops diagnostic imaging agents and targeted therapies for neurodegenerative disorders, including Alzheimer’s disease and related tauopathies. Its research programs target abnormal brain proteins through PET tracers, antibodies and protein-degradation approaches. Its diagnostics branch, APN LifeSciences, works on tau imaging and AI-assisted brain-health diagnostics. APRINOIA’s October 2026 website describes continued diagnostic and therapeutic work while announcing forthcoming updates.

Tokyo-based Keio University medical-school spinout founded in November 2016 that develops drugs and regenerative cell therapies for neurological disease. It uses patient-derived induced pluripotent stem cells to reproduce disease biology and screen or repurpose medicines for conditions including ALS and Alzheimer’s disease. Its regenerative-medicine programs develop iPS-derived neural cells for spinal cord injury and stroke; its KP8011 spinal-cord program was preparing for company-sponsored clinical trials in February 2026. Listed on the Tokyo Stock Exchange Growth Market in October 2023.

Tokyo-based biotechnology venture capital firm founded in May 2014 within the Daiwa Corporate Investment group. It invests in Japanese and Taiwanese drug-discovery and regenerative-medicine companies and helps commercialize academic research. Alongside financing existing ventures, it creates new biotech companies around research programs and supports clinical development, intellectual property, licensing, recruitment and business development. Its third Japan–Taiwan biotech fund was announced in June 2026.

Taiwan-based biotech investor with a legal background.

Biotech investor and founder of DCI Partners.

Supports business planning and management of fund-created biotech companies.

Pharmaceutical R&D planning background; joined DCI Partners in 2018.

Former Daiwa Securities M&A adviser; joined DCI Partners in 2015.

Pharmacist with pharmaceutical business-development experience.

Biological-sciences graduate specializing in protein function; joined in 2024.

Japan–Taiwan biotech investor based in Taiwan since 2008.

DCI Partners co-founder investing in Japanese and Taiwanese biotech.

Pharmaceutical-sciences doctorate; invests in Taiwanese life-sciences companies.

Joined DCI Partners in 2017 following private-equity work.

Lucas Harrington is a member of the SciFounders team and cofounder of Mammoth Biosciences. His SciFounders biography describes a UC Berkeley PhD in Jennifer Doudna's laboratory and incubation of Preventive, a company focused on preventing genetic diseases before birth.

Matt Krisiloff is a member of the SciFounders team and CEO of Conception, which is developing methods to turn pluripotent stem cells into viable human eggs. His SciFounders biography describes prior leadership of Y Combinator Research and experience helping science startups.

Bill Midgette is listed by GRA Venture Fund as Director. The Fund's public leadership directory establishes this affiliation. Other employers described in the biography are separate affiliations.

Charles Ogburn is listed by GRA Venture Fund as Director. The Fund's public leadership directory establishes this affiliation. Other employers described in the biography are separate affiliations.

David M. Ratcliffe is listed by GRA Venture Fund as Director. The Fund's public leadership directory establishes this affiliation. Other employers described in the biography are separate affiliations.

F. Duane Ackerman is listed by GRA Venture Fund as Director. The Fund's public leadership directory establishes this affiliation. Other employers described in the biography are separate affiliations.

Frances Gail Rogers is listed by GRA Venture Fund as Chair of the Board. The Fund's public leadership directory establishes this affiliation. Other employers described in the biography are separate affiliations.

Kurt Jacobus is listed by GRA Venture Fund as Senior Advisor. The Fund's public leadership directory establishes this affiliation. Other employers described in the biography are separate affiliations.

Connor Seabrook is listed by GRA Venture Fund as Managing Director. The Fund's public leadership directory establishes this affiliation. Other employers described in the biography are separate affiliations.

GRA Venture Fund, LLC is a public-private venture capital fund launched by the Georgia Research Alliance in 2009 to invest in research-driven Georgia startups. Its technology and life-science portfolio includes AI healthcare applications, advanced thermal materials, neural-interface devices, neurodegeneration therapeutics and autism diagnostics. The Fund is separate from GRA's venture development program, which provides milestone-based grants and loans to university projects. Its public leadership directory identifies Managing Director Connor Seabrook, Senior Advisors Kurt Jacobus and Michelle Jarrard, Board Chair Frances Gail Rogers, and Directors F. Duane Ackerman, Bill Midgette, Charles Ogburn and David M. Ratcliffe. The Fund's current FAQ states that it is fully invested and is no longer considering new investments. Its historical capital disclosures describe a $7.5 million State of Georgia evergreen investment and $11.8 million from other investors at launch, followed by a second raise of more than $25 million in 2015. GRA was a named participant in BioCircuit Technologies' private financing at its independent launch in 2019 and $9 million Series Seed round in September 2022.

Tokyo-based independent venture capital firm founded in October 2015 that invests in Japanese seed, early-stage and growth companies. It focuses on IT services, university spinouts and deep technology, including AI software, advanced manufacturing and life sciences. Drawing on private-equity and investment-banking experience, it combines business analysis and ongoing financing with hands-on help in hiring, organization, operations and capital strategy. Its third Unicorn Fund completed fundraising at ¥26 billion in November 2025.

Japanese life-science venture capital firm founded in March 2004 with offices in Tokyo and Cambridge, Massachusetts. It invests in early-stage biotech, medical devices, diagnostics, digital health and healthcare services, supporting research-based companies from scientific discovery through clinical development and commercial growth. Its team provides hands-on help with business and R&D strategy, partnerships, investor syndication and expansion between Japan and the United States. Its fourth healthcare fund closed at ¥20 billion in October 2025.

Tokyo-based clinical-stage biotechnology company founded in April 2022 to develop treatments for dementia and other central nervous system disorders from Tohoku University research. Its lead candidate NTX-083 is an orally administered small molecule being developed for Alzheimer’s disease with a new mechanism of action. The company conducts clinical development, builds backup compounds and explores additional brain-disease targets. By June 2026 it reported completing single- and multiple-dose Phase 1 studies in healthy adults and planned a US Phase 1b study in Alzheimer’s patients; cognitive benefits and disease modification remain development goals.

Venture Partner at Fast Track Initiative since January 2015, overseeing HealthTech investments. Previously led Microsoft Japan’s healthcare business and worked in strategic business planning and pharmaceutical digital transformation at Bayer Japan; began his career at Mitsubishi Electric. Meiji University commerce graduate and MBA.

Biotech investor with research experience in neurological regenerative medicine.

Dementia Discovery Fund venture partner, also known as Tetsuyuki Maruyama; Alzheimer's Disease Data Initiative executive director and former Takeda drug discovery head.

James Nahirny is publicly listed by BioCircuit Technologies as Director. This affiliation reflects the company's published board directory; continuation of an independent board after the October 2026 Axogen acquisition is not established by that listing.

Michelle Jarrard is publicly listed by BioCircuit Technologies as CEO and Director. This affiliation reflects the company's published board directory; continuation of an independent board after the October 2026 Axogen acquisition is not established by that listing.

Mike Masters is publicly listed by BioCircuit Technologies as Director. This affiliation reflects the company's published board directory; continuation of an independent board after the October 2026 Axogen acquisition is not established by that listing. Michael W. Masters is managing member and controlling founder of Masters Special Situations and founder of Masters Capital Management. The firms and his personal investments are distinct. His existing BioCircuit board biography and portrait are preserved.

Glenn H. Epstein is publicly listed by BioCircuit Technologies as Director. This affiliation reflects the company's published board directory; continuation of an independent board after the October 2026 Axogen acquisition is not established by that listing.

Thomas O'Brien is publicly listed by BioCircuit Technologies as Board Chair. This affiliation reflects the company's published board directory; continuation of an independent board after the October 2026 Axogen acquisition is not established by that listing.

BioCircuit Technologies is an Atlanta medical-device company developing tissue-repair and neuromodulation technologies. Its commercial NerveTape device combines a porcine collagen matrix with precision Nitinol microhooks to connect severed peripheral nerves without microsutures; FDA 510(k) clearances were issued in July 2022 and February 2024. BioCircuit also develops nerve-protection biomaterials and historically pursued bioelectronic spinal-reflex conditioning for neurological rehabilitation. Its own public board directory lists CEO Michelle Jarrard, Board Chair Thomas O'Brien, Glenn H. Epstein, Mike Masters and James Nahirny. BioCircuit launched independently from Axion Biosystems in June 2019, with Jim Ross named as a cofounder. A September 2022 $9 million Series Seed round included Mike Masters, GRA Venture Fund and Alsora Capital. NIH records document research grants for NerveTape, commercialization readiness, spinal-reflex conditioning and lymphovenous anastomosis. Axogen completed its acquisition on October 1, 2026 under an agreement specifying $200 million cash consideration subject to adjustments; the agreement required a separate spin-out of BioCircuit's electronics research business.

Kathy Weiler is listed by Axogen as Director. The company's public US leadership directory documents this affiliation; the portrait comes from its official international website.

Joseph (Adrian) Tyndall is listed by Axogen as Director. The company's public US leadership directory documents this affiliation; the portrait comes from its official international website.

Alan M. Levine is listed by Axogen as Director. The company's public US leadership directory documents this affiliation; the portrait comes from its official international website.

John H. Johnson is listed by Axogen as Director. The company's public US leadership directory documents this affiliation; the portrait comes from its official international website. John Johnson is listed by HealthQuest Capital as Operating Partner. The primary biography explicitly identifies current Axogen board service and prior Strongbridge/ImClone leadership, matching existing John H. Johnson.

Amy Wendell is listed by Axogen as Director. The company's public US leadership directory documents this affiliation; the portrait comes from its official international website.

William Burke is listed by Axogen as Director. The company's public US leadership directory documents this affiliation; the portrait comes from its official international website.

Paul G. Thomas is listed by Axogen as Chairman of the Board. The company's public US leadership directory documents this affiliation; the portrait comes from its official international website.

Jesse Bishop is listed by Axogen as Vice President of Regulatory. The company's public US leadership directory documents this affiliation; the portrait comes from its official international website.

Rick Ditto is listed by Axogen as VP, Global Health Economics, Reimbursement & Policy. The company's public US leadership directory documents this affiliation; the portrait comes from its official international website.

Al Jacks is listed by Axogen as Vice President of Quality. The company's public US leadership directory documents this affiliation; the portrait comes from its official international website.

Amalia De Luca is listed by Axogen as Vice President of Planning and Business Development. The company's public US leadership directory documents this affiliation; the portrait comes from its official international website.

Craig Swandal is listed by Axogen as Senior Vice President, Operations. The company's public US leadership directory documents this affiliation; the portrait comes from its official international website.

Stacy Arnold is listed by Axogen as Vice President of Product Development and Research. The company's public US leadership directory documents this affiliation; the portrait comes from its official international website.

Erick DeVinney is listed by Axogen as Chief Scientific Officer. The company's public US leadership directory documents this affiliation; the portrait comes from its official international website.

Ivica Ducic is listed by Axogen as Chief Medical Officer. The company's public US leadership directory documents this affiliation; the portrait comes from its official international website.

Doris Quackenbush is listed by Axogen as Chief Revenue Officer. The company's public US leadership directory documents this affiliation; the portrait comes from its official international website.

Jens Schroeder Kemp is listed by Axogen as Chief Marketing Officer. The company's public US leadership directory documents this affiliation; the portrait comes from its official international website.

Lindsey Hartley is listed by Axogen as Chief Financial Officer. The company's public US leadership directory documents this affiliation; the portrait comes from its official international website.

Marc Began is listed by Axogen as Executive Vice President and General Counsel. The company's public US leadership directory documents this affiliation; the portrait comes from its official international website.

Axogen is a Nasdaq-listed medical technology company focused on peripheral nerve regeneration and repair. Its products include Avance acellular nerve allograft, Axoguard nerve connectors, protectors and caps, and Avive+ soft tissue matrix. The company received FDA biologics-license approval for Avance in December 2025, including accelerated approval for specified larger sensory gaps and mixed or motor nerve discontinuities. Led by President and CEO Michael Dale, its public directories list 13 executives and eight directors, with Dale serving in both groups. Axogen invested $7 million in Trace Biosciences on July 28, 2026, supporting investigational nerve-specific surgical imaging. It completed the acquisition of BioCircuit Technologies on October 1, 2026, adding the FDA-cleared NerveTape sutureless nerve-repair device. The announced acquisition agreement specified $200 million cash consideration, subject to customary adjustments, and a spin-out of BioCircuit's electronics research business. Axogen closed a $142.6 million gross public equity offering in January 2026 and priced a separate $208.675 million base public offering in September to fund the acquisition.

Michael Dale is listed by Axogen as President, Chief Executive Officer and Board Director. The company's public US leadership directory documents this affiliation; the portrait comes from its official international website.

Tokyo-based university venture capital firm founded in December 2015 to commercialize academic research and inventions. It invests in seed and early-stage technology startups across healthcare, drug discovery, AI, robotics, space and clean technology, supporting teams from research commercialization through business growth. Initially focused on Keio University spinouts, it broadened its scope to research-based companies beyond Keio in 2020. Its third fund applies impact measurement and management to investments aimed at improving health and well-being alongside financial returns.

Tokyo-based medical-device company founded in May 2018 from Keio University neuroscience research, formerly named Connect. It develops, manufactures and sells brain–machine interface rehabilitation equipment for people with severe paralysis after stroke. Its systems analyze scalp EEG signals using AI and synchronize detected movement intentions with a robotic hand device, providing feedback for repeated rehabilitation exercises. Its product range includes medical and functional-training BMI systems for the hand; it is also developing a therapeutic BMI intended to improve motor recovery.

Palo Alto-based neuroscience and medical-device company developing objective brain-function measurements for psychiatric care and CNS drug development. Its UB ERP System combines a wearable dry-electrode EEG cap with brief tasks that evoke event-related potentials, measuring domains such as attention, reward, emotion and cognitive control. It develops neurotyping and treatment-response research tools to help characterize patients and clinical-trial populations. Its website distinguishes cleared P300 ERP measurement from investigational neurotyping, response prediction and other ERP features.

Brynn Putnam is listed by The Venture Collective as Venture Partner. This role belongs to TVC's separately identified venture partner network.

Evan Segal is listed by The Venture Collective as Venture Partner. This role belongs to TVC's separately identified venture partner network.

Sanjiv Sanghavi is listed by The Venture Collective as Venture Partner. This role belongs to TVC's separately identified venture partner network.

Seanna Thompson is listed by The Venture Collective as Venture Partner. This role belongs to TVC's separately identified venture partner network.

Erica Dorfman is listed by The Venture Collective as Venture Partner. This role belongs to TVC's separately identified venture partner network. Erica Dorfman is published in Coalition Operators’ external operator network. Fintech exec who’s helped scale the companies reshaping how money moves. Published career affiliations: Brex, Tally, SoFi. Network membership is distinct from a firm employee or general partner role; listed career affiliations do not establish current employment at every named company.

James Gillespie is listed by The Venture Collective as Venture Partner. This role belongs to TVC's separately identified venture partner network.

Kristin Thayer is listed by The Venture Collective as Venture Partner. This role belongs to TVC's separately identified venture partner network.

Andrew Trader is listed by The Venture Collective as Venture Partner. This role belongs to TVC's separately identified venture partner network.

Paula Sutter is listed by The Venture Collective as Senior Advisor. This affiliation is documented in TVC's current public team directory.

Chris Ghadban is listed by The Venture Collective as Principal. This affiliation is documented in TVC's current public team directory.

Luke Lloyd-Davies is listed by The Venture Collective as Chairman. This affiliation is documented in TVC's current public team directory.

Cat Middleton is listed by The Venture Collective as General Partner. This affiliation is documented in TVC's current public team directory.

Elliot Richmond is listed by The Venture Collective as Senior Advisor. This affiliation is documented in TVC's current public team directory.

Emily Aronin is listed by The Venture Collective as Associate. This affiliation is documented in TVC's current public team directory.

Stephanie Sarelakos is listed by The Venture Collective as Partner. This affiliation is documented in TVC's current public team directory.

Gina Shekerdemian is listed by The Venture Collective as Founding Partner. This affiliation is documented in TVC's current public team directory.

Pete Ondishin is listed by The Venture Collective as Chief Financial Officer. This affiliation is documented in TVC's current public team directory.

Ines Ullmo is listed by The Venture Collective as Associate. This affiliation is documented in TVC's current public team directory.

Nicole Seligman is listed by The Venture Collective as Executive in Residence. This affiliation is documented in TVC's current public team directory.

Nicholas Shekerdemian is listed by The Venture Collective as Founding Partner. This affiliation is documented in TVC's current public team directory.

Harsh Sant is Research Associate at Trace Biosciences, which develops nerve-specific fluorescent imaging agents for surgery. The company's public team directory establishes this role.

Hanna Adler is Marketing and Research Associate at Trace Biosciences, which develops nerve-specific fluorescent imaging agents for surgery. The company's public team directory establishes this role.

Diego Jacho is Post Doctoral Scholar at Trace Biosciences, which develops nerve-specific fluorescent imaging agents for surgery. The company's public team directory establishes this role.

Ge Huang is Senior Research Associate at Trace Biosciences, which develops nerve-specific fluorescent imaging agents for surgery. The company's public team directory establishes this role.

Grace Hubbell is Staff Scientist at Trace Biosciences, which develops nerve-specific fluorescent imaging agents for surgery. The company's public team directory establishes this role.

Scott Houston is Head of Clinical Operations at Trace Biosciences, which develops nerve-specific fluorescent imaging agents for surgery. The company's public team directory establishes this role.

Veronica Torres is Clinical Project Manager at Trace Biosciences, which develops nerve-specific fluorescent imaging agents for surgery. The company's public team directory establishes this role.

Lawrence Trost is Head of Toxicology at Trace Biosciences, which develops nerve-specific fluorescent imaging agents for surgery. The company's public team directory establishes this role.

Bryce Timm is Director of Research at Trace Biosciences, which develops nerve-specific fluorescent imaging agents for surgery. The company's public team directory establishes this role.

Mark Sorenson is Head of CMC Development at Trace Biosciences, which develops nerve-specific fluorescent imaging agents for surgery. The company's public team directory establishes this role.

Lei Wang is Cofounder and Chief Technology Officer at Trace Biosciences, which develops nerve-specific fluorescent imaging agents for surgery. The company's public team directory establishes this role.

Trace Biosciences is an Oregon biotechnology company developing Nerve Trace, near-infrared fluorescent imaging agents designed to highlight nerves during surgery, including nerves obscured by tissue or blood. Its nerve-specific small molecules are intended to help surgeons avoid nerve injury and integrate with existing surgical fluorescence imaging systems. Cofounders Connor Barth, Summer Gibbs and Lei Wang lead a 13-person publicly listed team spanning chemistry, manufacturing, toxicology, clinical operations and research. The company reported FDA investigational new drug clearance in December 2025 and Phase I clinical development in July 2026; its agents remain investigational and are not FDA-approved products. Trace announced a Series A strategic investment from Axogen in July 2026. Its August 12 SEC filing reports $8,334,499 sold in an ongoing equity offering, distinct from the $16,234,498 offering target. Axogen separately disclosed a $7 million investment on July 28. Earlier financing includes a $400,000 SciFounders SAFE in 2021 and a combined $275,000 SAFE investment from Elevate Capital and ONAMI in 2023, documented in an NCI-hosted historical company profile. Trace also receives federal research funding; awards to predecessor grant recipient Inherent Targeting LLC are distinguished from grants expressly awarded or transferred to Trace Biosciences Inc.

Connor Barth is Cofounder and CEO at Trace Biosciences, which develops nerve-specific fluorescent imaging agents for surgery. The company's public team directory establishes this role.

Summer Gibbs is Cofounder and Chief Scientific Officer at Trace Biosciences, which develops nerve-specific fluorescent imaging agents for surgery. The company's public team directory establishes this role.

Director of product at Mon Ami. This product professional is kept separate from the namesake Apellis chief financial officer.

RNA interference researcher at UMass Medical School and co-recipient of the 2006 Nobel Prize in Physiology or Medicine for the discovery of RNA interference.

Co-founder of Blitzscaling Ventures. The March2026 SEC filing lists Jeffrey Abbott as a manager of the AI fund’s general partner.

Serves as Board Member at Paradigm Health, according to its current team directory.

Stanford biochemistry professor and former president of Merck Research Laboratories; named a Vaccine Company director in its 2024 filing.

Palo Alto-based venture firm formed in 2020 that invests in technology startups capable of rapidly building market leadership through distribution, viral growth, network effects and customer switching costs. Its founders developed the Blitzscaling framework at Stanford and in the associated book. The firm backs both scaling businesses and early-stage AI companies through its dedicated AI fund, with portfolio investments in AI agents, software, marketplaces and AI drug discovery.

Venture partner at Blitzscaling Ventures working with Korean startups, co-investors and limited partners. Sogang graduate and Fulbright MBA who founded BoxLadder; distinct from the namesake Axiom/Elevate executive.

Augie Sick is listed by ONAMI as Entrepreneur-in-Residence. The organization's own named staff biography establishes this affiliation.

Juanita Kurtin is listed by ONAMI as Entrepreneur-in-Residence. The organization's own named staff biography establishes this affiliation.

Shula Jaron is listed by ONAMI as Entrepreneur-in-Residence. The organization's own named staff biography establishes this affiliation.

Eileen Brewer is listed by ONAMI as Digital Media Creator. The organization's own named staff biography establishes this affiliation.

John Brewer Jr is listed by ONAMI as Entrepreneur-in-Residence. The organization's own named staff biography establishes this affiliation.

Danielle Clair is listed by ONAMI as Vice President, Operations. The organization's own named staff biography establishes this affiliation.

Jay Lindquist is listed by ONAMI as Executive Director. The organization's own named staff biography establishes this affiliation.

Skip Rung is listed by ONAMI as Chief Startup Officer and President. The organization's own named staff biography establishes this affiliation. His full name is Robert D. Rung; the official directory uses the familiar name Skip.

Oregon Nanoscience and Microtechnologies Institute, known as ONAMI, is an Oregon nonprofit commercialization and early-stage investment organization supported by Business Oregon, Oregon Lottery funding and the federal SSBCI program. It helps research-based companies develop science and technology into investable businesses, particularly in advanced materials, electronics, optics, biomedical devices and other deep-tech sectors. Its July 2025–June 2027 Center of Innovation Excellence Collaborative Fund program anticipates seven to eight pre-seed and seed investments, typically through SAFEs, convertible notes or restricted stock purchases, supported by technical diligence and mentoring. Check ranges and planned activity are not a disclosed final fund size. Its public directories name eight staff members, including Executive Director Jay Lindquist, President and Chief Startup Officer Skip Rung, Vice President of Operations Danielle Clair, digital-media staff and entrepreneurs in residence. ONAMI is a named participant in Neurosom's January 2026 bridge financing and publishes a broader historical technology portfolio requiring individual issuer verification. Its team biography describes origins in 2003, while its FAQ gives a 2005 formation date; an exact legal founding year has not been assigned.

Camille Guers-Renz appears in BEL's public Research Assistants Team directory, which includes University of Oregon student biographies referencing the 2024–2025 academic period. This is a documented public affiliation; current employment and any departure date have not been independently established.

Isaac Patchen appears in BEL's public Research Assistants Team directory, which includes University of Oregon student biographies referencing the 2024–2025 academic period. This is a documented public affiliation; current employment and any departure date have not been independently established.

Ella Hiebert appears in BEL's public Research Assistants Team directory, which includes University of Oregon student biographies referencing the 2024–2025 academic period. This is a documented public affiliation; current employment and any departure date have not been independently established.

Emi Eckhaus appears in BEL's public Research Assistants Team directory, which includes University of Oregon student biographies referencing the 2024–2025 academic period. This is a documented public affiliation; current employment and any departure date have not been independently established.

Brain Electrophysiology Laboratory Company, LLC, branded BEL, is a Eugene, Oregon neuroscience technology company founded by Don Tucker in 2018. It develops high-density EEG instruments, wearable sleep recording and stimulation technology, source-imaging software and cloud research workflows. Products include BEL EEG System One, Geodesic Head Web, FLOW, SOURCERER and the Sleep WISP ecosystem. Its NEAT neural-network software automatically scores EEG sleep stages and received FDA 510(k) clearance under K250058 on April 10, 2025. The current company description identifies Don Tucker as founder and CEO and Phan Luu as Chief Science Officer; the April 2025 FDA clearance identifies Roman Shusterman as CTO. BEL's public research-assistant directory names five students, with biographies referencing the 2024–2025 academic period; their current employment has not been independently confirmed. BEL is a distinct affiliate of Neurosom under common control and licenses technologies to Neurosom in exchange for royalties and non-cash equity. Federal records identify BEL, rather than Neurosom, as the recipient of NIH SBIR awards for electrical neuromodulation, epilepsy surgical planning and sleep therapy for mild cognitive impairment. BEL also announced approximately $1.3 million of support within a larger $4.3 million Department of Defense sleep research project in November 2021. These research awards do not establish a private venture financing round.

Roman Shusterman is identified as Chief Technology Officer of Brain Electrophysiology Laboratory Company in the FDA's April 10, 2025 NEAT 001 clearance letter. BEL's research and workflow software talks also use the name Roma Shusterman. The FDA role is documented as of that filing; a newer company management roster has not been established.

Trevor Linnell appears in BEL's public Research Assistants Team directory, which includes University of Oregon student biographies referencing the 2024–2025 academic period. This is a documented public affiliation; current employment and any departure date have not been independently established.

US biotechnology company developing an AI and multi-omics platform to discover treatments for complex chronic and neuroimmune conditions. It combines longitudinal clinical information and biological samples from its Chronicle Biobank with large biological models to identify disease mechanisms, distinguish patient subgroups and guide therapeutic development. Its work aims to translate human biological data into targeted medicines; it remains a research and drug-discovery platform rather than an approved treatment provider.